tiprankstipranks
Pfizer Inc (IT:1PFE)
NYSE:1PFE
Italy Market
1PFE
Pfizer
RESEARCH TOOLSreports

Pfizer (1PFE) Stock Forecast & Price Target

9 Followers
See the Price Targets and Ratings of:

1PFE Analyst Ratings

Hold
22Ratings
Hold
7 Buy
13 Hold
2 Sell
Based on 22 analysts giving stock ratings to
Pfizer
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

1PFE Stock 12 Month Forecast

Average Price Target

€24.91
▲(7.46% Upside)
Based on 22 Wall Street analysts offering 12 month price targets for Pfizer in the last 3 months. The average price target is €24.91 with a high forecast of €31.04 and a low forecast of €21.56. The average price target represents a 7.46% change from the last price of €23.18.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"18":"€18","25":"€25","32":"€32","21.5":"€21.5","28.5":"€28.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":31.04026272,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€31.04</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":24.9088528,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€24.91</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21.555738,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€21.56</span>\n  </div></div>","useHTML":true}}],"tickPositions":[18,21.5,25,28.5,32],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.97,22.667712516923075,23.365425033846154,24.06313755076923,24.760850067692306,25.458562584615386,26.156275101538462,26.853987618461538,27.551700135384614,28.249412652307694,28.94712516923077,29.64483768615385,30.342550203076925,{"y":31.04026272,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.97,22.196065599999997,22.4221312,22.648196799999997,22.8742624,23.100327999999998,23.3263936,23.552459199999998,23.7785248,24.004590399999998,24.230656,24.456721599999998,24.6827872,{"y":24.9088528,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.97,21.93813369230769,21.906267384615383,21.874401076923075,21.84253476923077,21.810668461538462,21.778802153846154,21.746935846153846,21.715069538461538,21.68320323076923,21.651336923076926,21.619470615384618,21.58760430769231,{"y":21.555738,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":19.13,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 55, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.957,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 37, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.198,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 38, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.106,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 35, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.84,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 37, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.239,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 35, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.202,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 34, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.535,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 33, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.081,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 33, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.104,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.891,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.42,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 36, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.97,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 37, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€31.04Average Price Target€24.91Lowest Price Target€21.56
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays Analyst forecast on IT:1PFE
Emily Field
Barclays
Barclays
€21.56
Sell
-7.01%
Downside
Reiterated
06/15/26
Analysts Offer Insights on Healthcare Companies: Incyte (NASDAQ: INCY), Pfizer (NYSE: PFE) and MBX Biosciences, Inc. (NASDAQ: MBX)
Wells Fargo Analyst forecast on IT:1PFE
Mohit Bansal
Wells Fargo
Wells Fargo
€24.14
Hold
4.15%
Upside
Assigned
06/11/26
Analysts Offer Insights on Healthcare Companies: Omnicell (NASDAQ: OMCL), Oric Pharmaceuticals (NASDAQ: ORIC) and Pfizer (NYSE: PFE)
RBC Capital Analyst forecast on IT:1PFE
Trung Huynh
RBC Capital
RBC Capital
€21.56
Hold
-7.01%
Downside
Upgraded
06/09/26
Pfizer upgraded to Sector Perform from Underperform at RBC CapitalPfizer upgraded to Sector Perform from Underperform at RBC Capital
Bernstein Analyst forecast on IT:1PFE
Courtney Breen
Bernstein
Bernstein
―
Hold
―
Reiterated
06/09/26
Bernstein Remains a Hold on Pfizer (PFE)
Goldman Sachs Analyst forecast on IT:1PFE
Asad Haider
Goldman Sachs
Goldman Sachs
€22.42
Hold
-3.29%
Downside
Reiterated
06/08/26
Pfizer Obesity Franchise Shows Promise but Competition, Execution Risks Keep Rating at Hold and Price Target Unchanged at $26
Citi Analyst forecast on IT:1PFE
Geoff Meacham
Citi
Citi
€23.28
Hold
0.43%
Upside
Reiterated
06/07/26
Analysts Conflicted on These Healthcare Names: Cullinan Management (NASDAQ: CGEM) and Pfizer (NYSE: PFE)
BMO Capital Analyst forecast on IT:1PFE
Evan Seigerman
BMO Capital
BMO Capital
€22.45→€29.32
Buy
26.47%
Upside
Reiterated
06/06/26
BMO Capital Sticks to Their Buy Rating for Pfizer (PFE)
Cantor Fitzgerald Analyst forecast on IT:1PFE
Carter Gould
Cantor Fitzgerald
Cantor Fitzgerald
€23.28
Hold
0.43%
Upside
Reiterated
06/06/26
Analysts Offer Insights on Healthcare Companies: Cullinan Management (NASDAQ: CGEM), Pfizer (NYSE: PFE) and Novo Nordisk (NYSE: NVO)
Guggenheim Analyst forecast on IT:1PFE
Vamil Divan
Guggenheim
Guggenheim
€31.04
Buy
33.91%
Upside
Reiterated
06/01/26
Jefferies Analyst forecast on IT:1PFE
Akash Tewari
Jefferies
Jefferies
€30.18
Buy
30.19%
Upside
Reiterated
06/01/26
Jefferies Reaffirms Their Buy Rating on Pfizer (PFE)
J.P. Morgan Analyst forecast on IT:1PFE
Chris Schott
J.P. Morgan
J.P. Morgan
€25.87
Hold
11.59%
Upside
Reiterated
06/01/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Pfizer (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX)
UBS Analyst forecast on IT:1PFE
Michael Yee
UBS
UBS
€23.28
Hold
0.43%
Upside
Reiterated
05/30/26
Analyst Maintains Hold on Pfizer, Keeps Price Target Unchanged at $27 Amid Pipeline Uncertainties
Scotiabank Analyst forecast on IT:1PFE
Louise Chen
Scotiabank
Scotiabank
€25.87
Buy
11.59%
Upside
Reiterated
05/28/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Wolfe Research Analyst forecast on IT:1PFE
Alexandria Hammond
Wolfe Research
Wolfe Research
€21.56→€22.42
Sell
-3.29%
Downside
Reiterated
05/13/26
Pfizer price target raised to $26 from $25 at Wolfe ResearchPfizer price target raised to $26 from $25 at Wolfe Research
Berenberg Bank Analyst forecast on IT:1PFE
Kerry Holford
Berenberg Bank
Berenberg Bank
€21.56
Hold
-7.01%
Downside
Reiterated
05/08/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: CSL (Other OTC: CMXHF), Roche Holding AG (Other OTC: RHHVF) and Pfizer (NYSE: PFE)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays Analyst forecast on IT:1PFE
Emily Field
Barclays
Barclays
€21.56
Sell
-7.01%
Downside
Reiterated
06/15/26
Analysts Offer Insights on Healthcare Companies: Incyte (NASDAQ: INCY), Pfizer (NYSE: PFE) and MBX Biosciences, Inc. (NASDAQ: MBX)
Wells Fargo Analyst forecast on IT:1PFE
Mohit Bansal
Wells Fargo
Wells Fargo
€24.14
Hold
4.15%
Upside
Assigned
06/11/26
Analysts Offer Insights on Healthcare Companies: Omnicell (NASDAQ: OMCL), Oric Pharmaceuticals (NASDAQ: ORIC) and Pfizer (NYSE: PFE)
RBC Capital Analyst forecast on IT:1PFE
Trung Huynh
RBC Capital
RBC Capital
€21.56
Hold
-7.01%
Downside
Upgraded
06/09/26
Pfizer upgraded to Sector Perform from Underperform at RBC CapitalPfizer upgraded to Sector Perform from Underperform at RBC Capital
Bernstein Analyst forecast on IT:1PFE
Courtney Breen
Bernstein
Bernstein
―
Hold
―
Reiterated
06/09/26
Bernstein Remains a Hold on Pfizer (PFE)
Goldman Sachs Analyst forecast on IT:1PFE
Asad Haider
Goldman Sachs
Goldman Sachs
€22.42
Hold
-3.29%
Downside
Reiterated
06/08/26
Pfizer Obesity Franchise Shows Promise but Competition, Execution Risks Keep Rating at Hold and Price Target Unchanged at $26
Citi Analyst forecast on IT:1PFE
Geoff Meacham
Citi
Citi
€23.28
Hold
0.43%
Upside
Reiterated
06/07/26
Analysts Conflicted on These Healthcare Names: Cullinan Management (NASDAQ: CGEM) and Pfizer (NYSE: PFE)
BMO Capital Analyst forecast on IT:1PFE
Evan Seigerman
BMO Capital
BMO Capital
€22.45→€29.32
Buy
26.47%
Upside
Reiterated
06/06/26
BMO Capital Sticks to Their Buy Rating for Pfizer (PFE)
Cantor Fitzgerald Analyst forecast on IT:1PFE
Carter Gould
Cantor Fitzgerald
Cantor Fitzgerald
€23.28
Hold
0.43%
Upside
Reiterated
06/06/26
Analysts Offer Insights on Healthcare Companies: Cullinan Management (NASDAQ: CGEM), Pfizer (NYSE: PFE) and Novo Nordisk (NYSE: NVO)
Guggenheim Analyst forecast on IT:1PFE
Vamil Divan
Guggenheim
Guggenheim
€31.04
Buy
33.91%
Upside
Reiterated
06/01/26
Jefferies Analyst forecast on IT:1PFE
Akash Tewari
Jefferies
Jefferies
€30.18
Buy
30.19%
Upside
Reiterated
06/01/26
Jefferies Reaffirms Their Buy Rating on Pfizer (PFE)
J.P. Morgan Analyst forecast on IT:1PFE
Chris Schott
J.P. Morgan
J.P. Morgan
€25.87
Hold
11.59%
Upside
Reiterated
06/01/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Pfizer (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX)
UBS Analyst forecast on IT:1PFE
Michael Yee
UBS
UBS
€23.28
Hold
0.43%
Upside
Reiterated
05/30/26
Analyst Maintains Hold on Pfizer, Keeps Price Target Unchanged at $27 Amid Pipeline Uncertainties
Scotiabank Analyst forecast on IT:1PFE
Louise Chen
Scotiabank
Scotiabank
€25.87
Buy
11.59%
Upside
Reiterated
05/28/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Wolfe Research Analyst forecast on IT:1PFE
Alexandria Hammond
Wolfe Research
Wolfe Research
€21.56→€22.42
Sell
-3.29%
Downside
Reiterated
05/13/26
Pfizer price target raised to $26 from $25 at Wolfe ResearchPfizer price target raised to $26 from $25 at Wolfe Research
Berenberg Bank Analyst forecast on IT:1PFE
Kerry Holford
Berenberg Bank
Berenberg Bank
€21.56
Hold
-7.01%
Downside
Reiterated
05/08/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: CSL (Other OTC: CMXHF), Roche Holding AG (Other OTC: RHHVF) and Pfizer (NYSE: PFE)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Pfizer

3 Months
Vamil DivanGuggenheim
Success Rate
25/35 ratings generated profit
71%
Average Return
+3.42%
Copying Vamil Divan's trades and holding each position for 3 Months would result in 71.43% of your transactions generating a profit, with an average return of +3.42% per trade.
1 Year
Vamil DivanGuggenheim
Success Rate
27/35 ratings generated profit
77%
Average Return
+6.57%
Copying Vamil Divan's trades and holding each position for 1 Year would result in 77.14% of your transactions generating a profit, with an average return of +6.57% per trade.
2 Years
Akash TewariJefferies
Success Rate
19/23 ratings generated profit
83%
Average Return
+7.37%
Copying Akash Tewari's trades and holding each position for 2 Years would result in 82.61% of your transactions generating a profit, with an average return of +7.37% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

1PFE Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
0
0
0
0
0
Buy
13
13
18
21
18
Hold
33
30
32
36
37
Sell
2
2
5
6
8
Strong Sell
0
0
0
0
0
total
48
45
55
63
63
In the current month, 1PFE has received 18 Buy Ratings, 37 Hold Ratings, and 8 Sell Ratings. 1PFE average Analyst price target in the past 3 months is 24.91.
Each month's total comprises the sum of three months' worth of ratings.

1PFE Financial Forecast

1PFE Earnings Forecast

Next quarter’s earnings estimate for 1PFE is €0.58 with a range of €0.53 to €0.65. The previous quarter’s EPS was €0.65. 1PFE beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year 1PFE has Performed in-line its overall industry.
Next quarter’s earnings estimate for 1PFE is €0.58 with a range of €0.53 to €0.65. The previous quarter’s EPS was €0.65. 1PFE beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year 1PFE has Performed in-line its overall industry.

1PFE Sales Forecast

Next quarter’s sales forecast for 1PFE is €12.43B with a range of €12.03B to €12.65B. The previous quarter’s sales results were €12.44B. 1PFE beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year 1PFE has Performed in-line its overall industry.
Next quarter’s sales forecast for 1PFE is €12.43B with a range of €12.03B to €12.65B. The previous quarter’s sales results were €12.44B. 1PFE beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year 1PFE has Performed in-line its overall industry.

1PFE Stock Forecast FAQ

What is IT:1PFE’s average 12-month price target, according to analysts?
Based on analyst ratings, Pfizer Inc’s 12-month average price target is 24.91.
    What is IT:1PFE’s upside potential, based on the analysts’ average price target?
    Pfizer Inc has 7.46% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Pfizer Inc a Buy, Sell or Hold?
          Pfizer Inc has a consensus rating of Hold, which is based on 7 buy ratings, 13 hold ratings and 2 sell ratings.
            What is Pfizer Inc’s share price target?
            The average share price target for Pfizer Inc is 24.91. This is based on 22 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €31.04 ,and the lowest forecast is €21.56. The average share price target represents 7.46% Increase from the current price of €23.18.
              What do analysts say about Pfizer Inc?
              Pfizer Inc’s analyst rating consensus is a Hold. This is based on the ratings of 22 Wall Streets Analysts.
                How can I buy shares of Pfizer Inc?
                To buy shares of IT:1PFE, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.